HIV Infection Clinical Trial
Official title:
See Detailed Description.
Verified date | October 2010 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.
Status | Completed |
Enrollment | 211 |
Est. completion date | June 2008 |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Subjects with HIV-1 infection. - Are willing and able to understand and provide written consent prior to participation in this study. Exclusion criteria: - Are pregnant or breastfeeding. - Have an active AIDS condition, pancreatitis, poor kidney function, or clinically relevant hepatitis. - Have certain medical conditions that may make participation unsafe. - Take medication that may interact with the study medication. - Have a history of allergy to any of the study drugs or any excipients therein. - Other inclusion/exclusion criteria to be evaluated by the physician. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Puerto Rico | GSK Investigational Site | Ponce | |
Puerto Rico | GSK Investigational Site | San Juan | |
United States | GSK Investigational Site | Akron | Ohio |
United States | GSK Investigational Site | Allentown | Pennsylvania |
United States | GSK Investigational Site | Atlanta | Georgia |
United States | GSK Investigational Site | Baltimore | Maryland |
United States | GSK Investigational Site | Baltimore | Maryland |
United States | GSK Investigational Site | Beverly Hills | California |
United States | GSK Investigational Site | Chicago | Illinois |
United States | GSK Investigational Site | Chicago | Illinois |
United States | GSK Investigational Site | Chicago | Illinois |
United States | GSK Investigational Site | Columbia | South Carolina |
United States | GSK Investigational Site | Dallas | Texas |
United States | GSK Investigational Site | Dallas | Texas |
United States | GSK Investigational Site | Denver | Colorado |
United States | GSK Investigational Site | Detroit | Michigan |
United States | GSK Investigational Site | Fort Lauderdale | Florida |
United States | GSK Investigational Site | Fort Lauderdale | Florida |
United States | GSK Investigational Site | Fort Myers | Florida |
United States | GSK Investigational Site | Fort Worth | Texas |
United States | GSK Investigational Site | Fountain Valley | California |
United States | GSK Investigational Site | Garden Grove | California |
United States | GSK Investigational Site | Hampton | Virginia |
United States | GSK Investigational Site | Harlingen | Texas |
United States | GSK Investigational Site | Hillsborough | New Jersey |
United States | GSK Investigational Site | Hollywood | Florida |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Houston | Texas |
United States | GSK Investigational Site | Indianapolis | Indiana |
United States | GSK Investigational Site | Lansing | Michigan |
United States | GSK Investigational Site | Little Rock | Arkansas |
United States | GSK Investigational Site | Los Angeles | California |
United States | GSK Investigational Site | Macon | Georgia |
United States | GSK Investigational Site | Maywood | Illinois |
United States | GSK Investigational Site | Miami | Florida |
United States | GSK Investigational Site | New York | New York |
United States | GSK Investigational Site | Newport Beach | California |
United States | GSK Investigational Site | Oakland Park | Florida |
United States | GSK Investigational Site | Orlando | Florida |
United States | GSK Investigational Site | Phoenix | Arizona |
United States | GSK Investigational Site | Sarasota | Florida |
United States | GSK Investigational Site | Somers Point | New Jersey |
United States | GSK Investigational Site | Spokane | Washington |
United States | GSK Investigational Site | Springfield | Massachusetts |
United States | GSK Investigational Site | Springfield | Massachusetts |
United States | GSK Investigational Site | Tampa | Florida |
United States | GSK Investigational Site | Tarzana | California |
United States | GSK Investigational Site | Valhalla | New York |
United States | GSK Investigational Site | Washington | District of Columbia |
United States | GSK Investigational Site | West Hollywood | California |
United States | GSK Investigational Site | West Palm Beach | Florida |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 | Virologic failure was defined as two consecutive plasma HIV-1 RNA measures greater than 400 copies/milliliter (mL) separated by at least 2 to 4 week. The percentage of participants not meeting the virologic failure definition was estimated with stratification by the six randomization strata using Mantel-Haenszel weights and the missing/discontinuation equals failure (MD=F) analysis. Missing/discontinuation values were considered failures. | Week 24 | No |
Secondary | Percentage of Participants With Plasma Human Immunodeficiency Virus, Type 1, Ribonucleic Acid (HIV-1 RNA) <400 Copies/mL at Week 24, Time to Loss of Virologic Response (TLOVR) Analysis | A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants with plasma HIV-1 RNA <400 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata. | Week 24 | No |
Secondary | Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 24, TLOVR Analysis | A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants plasma with HIV-1 RNA <50 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata. | Week 24 | No |
Secondary | Mean Change From Baseline of log10 Copies/mL Plasma HIV-1 RNA Levels at Week 24, Observed Analysis | A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. Change from baseline was defined as plasma HIV-1 RNA level at Week 24 minus plasma HIV-1 RNA level at baseline. | Baseline and Week 24 | No |
Secondary | Median Change From Baseline of CD4+ Cell Count at Week 24, Observed Analysis | A blood sample was drawn to determine the CD4+ cell count at week 24. Change from baseline was defined as CD4+ cell count at Week 24 minus CD4+ cell count at baseline. | Baseline and Week 24 | No |
Secondary | Number of Participants Who Discontinued Treatment Due to Adverse Events Through Week 24 | The number of participants who prematurely discontinued study drug due to adverse events was tabulated. Data are summarized by individual adverse event. Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. | Baseline through Week 24 | No |
Secondary | Number of Participants With Grade 2-4 Adverse Events Occurring in Greater Than or Equal to 2% of Subjects Through Week 24 | The number of participants who experienced any grades 2 to 4 adverse events was tabulated. Adverse events were graded based on the Division of Acquired Immunodeficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. | Baseline through Week 24 | No |
Secondary | Percent Change From Baseline in Total Cholesterol, High Density Lipoprotein (HDL), and Triglycerides at Week 24 | A blood sample was drawn to determine the cholesterol, HDL, triglycerides levels at Week 24. Percent change in total blood cholesterol, HDL, and triglycerides was defined as (lipid level at Week 24 minus level at baseline) divided by level at baseline x 100%. | Baseline and Week 24 | No |
Secondary | Percent Change From Baseline in Low Density Lipoprotein (LDL) at Week 24 | A blood sample was drawn to determine the LDL level at Week 24. Percent change in LDL was defined as (LDL level at Week 24 minus level at baseline) divided by level at baseline x 100%. | Baseline and Week 24 | No |
Secondary | Number of Participants With Plasma HIV-1 RNA Genotypic Mutations and Phenotypic Resistance at Time of Virologic Failure Not Present at Baseline | A blood sample was drawn for subjects failing to respond to therapy and the mutations present in the virus were identified. For each subject, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of virologic failure were tabulated by drug class. | Baseline through Week 24 | No |
Secondary | Steady-State Plasma Levels of Amprenavir (APV) and Ritonavir (RTV) Ctau at Weeks 12 and 24 | Blood samples were drawn at weeks 12 and 24 to determine the plasma levels of APV and RTV. Concentration at the end of the dosing interval at steady state (Ctau) was presented. | Weeks 12 and 24 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |